Pasireotide

Generic Name: Pasireotide

Brand Names: Signifor

Drug Type: Small Molecule

Chemical Formula: C_₅₈H_₆₆N_₁₀O_₉

CAS Number: 396091-73-9

Unique Ingredient Identifier: 98H1T17066

Background: Pasireotide is a synthetic long-acting cyclic hexapeptide with somatostatin-like activity. It is marketed as a diaspartate salt called Signifor, which is used in the treatment of Cushing's disease.

Indication: For the treatment of Cushing’s disease, specifically for those patients whom pituitary surgery has not been curative or is not an option.

Associated Conditions: Acromegaly, Cushing's Disease

Associated Therapies: -

Clinical Trials

Pasireotide as Maintenance Treatment in Synovial Sarcoma and Desmoplastic Small Round Cell Tumor

Phase 2

Not yet recruiting

Conditions: Desmoplastic Small Round Cell Tumor
Synovial Sarcoma

Interventions: Drug: Signifor

First Posted Date: 2024-06-13

Last Posted Date: 2024-06-13

Lead Sponsor: University Hospital Heidelberg

Target Recruit Count: 28

Registration Number: NCT06456359

Locations: 🇩🇪
National Center for Tumour Diseases, University Hospital Heidelberg, Heidelberg, Baden-Württemberg, Germany

A Study of Pasireotide in People With Prolactinoma

Phase 2

Recruiting

Conditions: Prolactin-Producing Pituitary Tumor

Interventions: Drug: Pasireotide
Other: SF-36 and HADS

First Posted Date: 2024-03-06

Last Posted Date: 2024-05-01

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 10

Registration Number: NCT06295952

Locations: 🇺🇸
Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, United States

and more 4 locations

A Study in Healthy Subjects to Assess the Safety, Tolerability, PK and PD of HTL0030310

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: HTL0030310
Drug: Pasireotide
Drug: Placebo

First Posted Date: 2019-02-20

Last Posted Date: 2020-10-27

Lead Sponsor: Heptares Therapeutics Limited

Target Recruit Count: 42

Registration Number: NCT03847207

Locations: 🇬🇧
Quotient Sciences, Nottingham, United Kingdom

Treatment Plan for an Individual Patient With Pasireotide for Hyperinsulinemic Hypoglycemia

Phase 1

Completed

Conditions: Post Gastrointestinal Tract Surgery Hypoglycaemia
Hyperinsulinemic Hypoglycemia

Interventions: Drug: Pasireotide

First Posted Date: 2017-04-06

Last Posted Date: 2021-09-29

Lead Sponsor: University of Colorado, Denver

Target Recruit Count: 1

Registration Number: NCT03103009

Locations: 🇺🇸
University of Colorado Denver, Aurora, Colorado, United States

Compassionate Use of SOM230 for Hyperinsulinemic/Hypoglycemia

Conditions: Congenital Hyperinsulinism

First Posted Date: 2016-07-15

Last Posted Date: 2022-07-29

Lead Sponsor: Montefiore Medical Center

Registration Number: NCT02835131

Locations: 🇺🇸
Montefiore Medical Center, Bronx, New York, United States

SOM230 Ectopic ACTH-producing Tumors

Phase 2

Withdrawn

Conditions: Ectopic ACTH Syndrome

Interventions: Drug: Pasireotide

First Posted Date: 2016-05-24

Last Posted Date: 2018-01-26

Lead Sponsor: Cedars-Sinai Medical Center

Registration Number: NCT02780882

Locations: 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States

Pasireotide Treatment for Neuroendocrine Tumor

Phase 4

Withdrawn

Conditions: Gastro-enteropancreatic Neuroendocrine Tumor

Interventions: Drug: Pasireotide
Drug: Diazoxide

First Posted Date: 2016-05-20

Last Posted Date: 2022-03-04

Lead Sponsor: University of Maryland, Baltimore

Registration Number: NCT02779257

HYPAR Trial - Hydrocortisone vs. Pasireotide in Reducing Pancreatic Surgery Complications

Phase 4

Active, not recruiting

Conditions: Pancreatic Fistula
Pancreatic Neoplasms

Interventions: Drug: Hydrocortisone
Drug: Pasireotide

First Posted Date: 2016-05-17

Last Posted Date: 2020-08-24

Lead Sponsor: Helsinki University Central Hospital

Target Recruit Count: 126

Registration Number: NCT02775227

Locations: 🇫🇮
Helsinki University Central Hospital, Helsinki, Finland

Reduction by Pasireotide of the Effluent Volume in High-output Enterostomy in Patients Refractory to Usual Medical Treatment

Phase 2

Completed

Conditions: Enterostomy

Interventions: Drug: Placebo
Drug: Pasireotide

First Posted Date: 2016-03-21

Last Posted Date: 2022-04-04

Lead Sponsor: Hospices Civils de Lyon

Target Recruit Count: 57

Registration Number: NCT02713776

Locations: 🇫🇷
Centre Leon Berard, Lyon, France
🇫🇷
Centre Hospitalier Lyon Sud, Pierre-Bénite, France
🇫🇷
Chu Albert Michallon, La Tronche, France

and more 11 locations

Pasireotide for the Treatment of Gastrointestinal Angiodysplasia in Endoscopic Treatment Failure

Phase 2

Completed

Conditions: Angiodysplasia

Interventions: Drug: Placebo
Drug: Pasireotide

First Posted Date: 2015-12-07

Last Posted Date: 2015-12-07

Lead Sponsor: Robert Benamouzig

Target Recruit Count: 24

Registration Number: NCT02622906

Locations: 🇫🇷
Société Française d'Endoscopie Digestive (SFED), Paris, France

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy